Sai Life Sciences (SAILIFE.NS) Stock Price

Sai Life Sciences Price

CLOSED
1,913.70
​
Market closed

Revenue has compounded at 23.6% per year over the past 5 years to 21.92 B INR. Earnings per share have grown at 41.7% per year over the last 5 years. Sai Life Sciences's net margin stands at 15.9%, up from 0.7% several years earlier. Analysts set a median price target of 1,183.20 INR, implying 38.2% below the current price. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.

Sai Life Sciences stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sai Life Sciences business model & stock analysis

Sai Life Sciences Ltd generates revenue through contract research, development, and manufacturing services for pharmaceutical and biotechnology companies. The company offers tailored services including Integrated Drug Discovery, Synthetic & medicinal chemistry, Biology, DMPK, Genotoxicity, General Toxicology, and Computational chemistry under its discovery and chemistry segment. Its CMC services encompass route scouting, process development, analytical development, process safety, stability studies, and commercial manufacturing. Customers are pharmaceutical and biotechnology firms seeking end-to-end solutions for drug development from discovery to commercial launch. The company operates as a CRO/CDMO, providing specialized services across the drug development lifecycle. Key service areas include discovery and chemistry, CMC, and technology transfer. Pharmaceutical and biotechnology customers purchase these services to accelerate their drug development processes and ensure regulatory compliance. The firm's offerings span early-phase supplies through to late-phase commercial manufacturing, supporting clients throughout the product lifecycle. Sai Life Sciences Ltd's business model focuses on delivering comprehensive solutions for drug development. The company's service portfolio includes discovery and chemistry services such as medicinal chemistry and DMPK, alongside CMC services like process development and commercial manufacturing. Pharmaceutical and biotechnology clients engage the firm for its expertise in navigating complex regulatory pathways and scaling production efficiently.

Frequently asked questions about Sai Life Sciences

Analysts currently set an average price target of 1,203.80 INR for the Sai Life Sciences stock (median: 1,183.20 INR), implying -37.1 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the Sai Life Sciences stock: 10 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Sai Life Sciences share trades at 18.67 EUR (1,913.70 INR).

The revenue of Sai Life Sciences is 21.92 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Sai Life Sciences is 3.49 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sai Life Sciences is currently 117.74. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sai Life Sciences stock.

The price-to-sales ratio (P/S) of Sai Life Sciences is currently 18.74. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sai Life Sciences stock.

The Eulerpool Quality Score for Sai Life Sciences is 6/10.

The ISIN of Sai Life Sciences is INE570L01029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Sai Life Sciences is SAILIFE.NS. The ticker symbol is used to trade Sai Life Sciences shares on the stock exchange.

Fair ValueTerminal
1,664.92 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website sailife.com
Country
Currency
INR
Initial public offering
Dec 18, 2024
ISIN
INE570L01029
Cusip
Y7451T124
Market capitalization
405.28 B INRMega Cap
52-Week Range
PEG
6.05
P/E ratio
P/Ee 2027
92.21
P/Ee 2028
71.49
P/Ee 2029
54.08
P/Se
15.19
EV/EBIT
87.67
P/B Ratio
16.32
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
12.59 %
Last updated Nov 19, 2026, 3:41 AM

Sai Life Sciences Peer Group